New Weight-Loss shot enters first human safety trial
NCT ID NCT07518589
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests an experimental drug called CMS-D008 in 110 healthy and overweight or obese adults. The main goal is to check safety and how the body processes the drug, not weight loss. Participants will receive either the drug or a placebo as injections, and researchers will monitor vital signs, lab tests, and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CMS-D008 (an experimental biologic injection)
- What this could lead to
- If successful, this could point toward a new treatment for weight management in overweight or obese adults.
- What could go wrong
- This is a very early Phase 1 trial focused on safety, not weight loss. It is small (110 people) and may not show meaningful benefits or lead to a marketed drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EVALUATE THE SAFETY AND TOLERABILITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection help tackle obesity and diabetes? a safety trial begins
- Can a single injection of SYH2082 help tackle obesity? a first-in-human trial puts safety to the test.
- App sends mindfulness exercises right after weight regain to keep dieters on track
- Sleep program aims to reduce pregnancy risks in african american women
- Could a Muscle-Building drug boost weight loss? new trial tests bimagrumab with semaglutide
- Weekly shot could help shed pounds in obesity trial